Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development (Q38010203)

From Wikidata

Jump to navigation Jump to search

scientific article published on June 2012

Language	Label	Description	Also known as
English	Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development	scientific article published on June 2012

Statements

scholarly article

1 reference

Europe PubMed Central

26 August 2017

Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development (English)

1 reference

Europe PubMed Central

26 August 2017

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Liz Alvarez-Lajonchere

1

1 reference

Europe PubMed Central

26 August 2017

Santiago Dueñas-Carrera

2

1 reference

Europe PubMed Central

26 August 2017

publication date

1 June 2012

1 reference

Europe PubMed Central

26 August 2017

International Reviews of Immunology

1 reference

Europe PubMed Central

26 August 2017

31

1 reference

Europe PubMed Central

26 August 2017

3

1 reference

Europe PubMed Central

26 August 2017

223-242

1 reference

Europe PubMed Central

26 August 2017

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

The natural history of hepatitis C virus infection: host, viral, and environmental factors

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Hepatic Transcriptome Analysis of Hepatitis C Virus Infection in Chimpanzees Defines Unique Gene Expression Patterns Associated with Viral Clearance

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Clearance of hepatitis C in chimpanzees is associated with intrahepatic T-cell perforin expression during the late acute phase

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Analyses of amino acid sequences in hypervariable region-1 of hepatitis C virus (HCV) in sera from chimpanzees infected three times with the same HCV strain

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Previously Infected Chimpanzees Are Not Consistently Protected against Reinfection or Persistent Infection after Reexposure to the Identical Hepatitis C Virus Strain

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Stable Cytotoxic T Cell Escape Mutation in Hepatitis C Virus Is Linked to Maintenance of Viral Fitness

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Hepatitis C virus with a naturally occurring single amino-acid substitution in the E2 envelope protein escapes neutralization by naturally-induced and vaccine-induced antibodies

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Evidence for Protection against Chronic Hepatitis C Virus Infection in Chimpanzees by Immunization with Replicating Recombinant Vaccinia Virus

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Animal models for hepatitis C and related liver disease

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

A target on the move: innate and adaptive immune escape strategies of hepatitis C virus

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Hepatitis C Virus (HCV)–Specific Immune Responses of Long‐Term Injection Drug Users Frequently Exposed to HCV

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Increased Cytotoxic T-Lymphocyte Epitope Variant Cross-Recognition and Functional Avidity Are Associated with Hepatitis C Virus Clearance

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

High Level of PD-1 Expression on Hepatitis C Virus (HCV)-Specific CD8+ and CD4+ T Cells during Acute HCV Infection, Irrespective of Clinical Outcome

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Adaptive immune responses in acute and chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Neutralizing antibody response during acute and chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Decreased IP-10 and elevated TGFbeta1 levels are associated with viral clearance following therapy in patients with hepatitis C virus

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Effect of IL-4 and IL-13 on collagen production in cultured LI90 human hepatic stellate cells

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Ribavirin improves early responses to peginterferon through improved interferon signaling

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Immune responses and immunity in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Isolation and functional analysis of circulating dendritic cells from hepatitis C virus (HCV) RNA-positive and HCV RNA-negative patients with chronic hepatitis C: role of antiviral therapy

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Genetic factors in mother-to-child transmission of HCV infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Hierarchy of baby-linked immunogenetic risk factors in the vertical transmission of hepatitis C virus

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Interferon lambdas: the next cytokine storm

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Design of therapeutic vaccines: hepatitis B as an example

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Vaccination for hepatitis C virus: closing in on an evasive target

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

A genetically humanized mouse model for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Hepatitis C virus replication in mice with chimeric human livers

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Chimeric GB virus B genomes containing hepatitis C virus p7 are infectious in vivo

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Characterization of natural killer cells in tamarins: a technical basis for studies of innate immunity

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Pathogenesis of Hepatitis C Virus Infection in Tupaia belangeri

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target.

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

HLA DR13 and HCV vertical infection

1 reference

https://api.crossref.org/works/10.3109%2F08830185.2012.680552

21 January 2018

Identifiers

10.3109/08830185.2012.680552

1 reference

Europe PubMed Central

26 August 2017

1 reference

Europe PubMed Central

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38010203&oldid=1737229847"